Key result
In vivo capsid antigen presentation from AAV8 transduction occurs with similar kinetics to AAV2, being detectable before 30 days and undetectable after 40 days.
Population
Animal models and in vitro cells used to study adeno-associated viral (AAV) transduction
Comparison
Engineered AAV8 and AAV2 vectors carrying the… vs Wild-type AAV8 and AAV2
Design
Preclinical
Follow-up
up to 40 days
Authors
Loading...
May guide preclinical AAV vector selection; leaves open human translation of capsid kinetics.
AAV2 and AAV8 vectors exhibit identical in vivo kinetics for capsid antigen presentation and CD8+ T cell proliferation, informing strategies to prevent immune-mediated elimination of transduced cells in gene therapy.
He et al. (2013) studied AAV vector gene therapy (preclinical model). AAV8OVA vector vs. AAV2OVA vector or control was evaluated on Kinetics of capsid antigen presentation (OT-1 T cell proliferation). In vivo capsid antigen presentation from AAV8 transduction occurs with similar kinetics to AAV2, being detectable before 30 days and undetectable after 40 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: